H. Lundbeck A/S

H. Lundbeck develops, produces and markets drugs for treating diseases of the central nervous system. Products include antidepressants for the treatment of depression, panic disorder, and prevention of relapse/recurrence. Antipsychotic products for psychotic disorders; schizophrenia, anxiety, restlessness and insomnia; treatment of psychotic disorders; acute psychotic episodes, exacerbation of psychotic disorders. Co.'s products inclue Cipralex®/Lexapro® for the treatment of depression and anxiety; Ebixa® for the treatment of Alzheimer's disease; Azilect® for the treatment of Parkinson's disease; Xenazine®, Sabril®, Saphris® Sycrest®, Onfi, and other.
  • TickerLUN
  • ISINDK0010287234
  • ExchangeNasdaq Nordic Copenhagen
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark
Anders Idborg ...
  • Casper Blom
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Olof Cederholm
  • Petter Nystrøm
  • Tobias Kaj

Talking Points - Bank Norwegian (Buy): Credit card lending book still to be valued

Lundbeck (Buy) Preview: All promising journeys have challenges Q2’20e PTP NOK 826m, boosted by LLP and trading TP up to NOK 79 (64) to reflect EPS chg./credit card book

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - All promising journeys have challenges

Expecting a mixed Q2’20 due to various headwinds… …but FY´20 guidance expectedly still well within reach BUY reiterated, new TP of DKK 278 (289)

Karl-Johan Bonnevier ...
  • Martin Arnell
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Viktor Trollsten

Northern Lights

Rune Majlund Dahl

Lundbeck (Buy, TP: DKK300.00) - Limited destocking effect in Q2e

We continue to expect solid underlying demand in Q2, and believe the destocking effect will be more evident in H2 following a limited impact in the second quarter. We forecast c1.3% YOY sales growth in Q2 (results due at c07:30 CET on 13 August). Despite ongoing Covid-19-related uncertainty, we expect the 2020 guidance to be raised. We reiterate our BUY and DKK300 target price.

For H LUNDBECK A/S, the environment deterioration entails a downgrade to Neutral

H LUNDBECK A/S (DK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 3 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date May 15, 2020, the closing price was DKK 244.80 and its expected value was estimated at DKK 232.88.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

Lundbeck(H) A S: 1 director sold

A director at Lundbeck(H) A S sold 5,000 shares at 242.240DKK and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boar...

Anders Idborg ...
  • Casper Blom
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Olof Cederholm
  • Petter Nystrøm
  • Tobias Kaj

Talking Points - Bank Norwegian (Buy): Credit card lending book still to be valued

Lundbeck (Buy) Preview: All promising journeys have challenges Q2’20e PTP NOK 826m, boosted by LLP and trading TP up to NOK 79 (64) to reflect EPS chg./credit card book

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - All promising journeys have challenges

Expecting a mixed Q2’20 due to various headwinds… …but FY´20 guidance expectedly still well within reach BUY reiterated, new TP of DKK 278 (289)

Rune Majlund Dahl

Lundbeck (Buy, TP: DKK300.00) - Limited destocking effect in Q2e

We continue to expect solid underlying demand in Q2, and believe the destocking effect will be more evident in H2 following a limited impact in the second quarter. We forecast c1.3% YOY sales growth in Q2 (results due at c07:30 CET on 13 August). Despite ongoing Covid-19-related uncertainty, we expect the 2020 guidance to be raised. We reiterate our BUY and DKK300 target price.

Anders Idborg ...
  • André Thormann
  • Derek Laliberté
  • Jan Erik Gjerland
  • Jannick Lindegaard Denholt
  • Jesper Birch-Jensen
  • Martin Kaland
  • Petter Nystrøm
  • Stefan Knutsson

Talking Points - Bang & Olufsen (Sell): Only when the tide goes out…

Atlas Copco (Hold) Company event: China close to normalised DKK 400m rights issue secured We still see major risk - SELL

Benjamin Silverstone ...
  • Jannick Lindegaard Denholt

Lundbeck - Solid performer with COVID-19 side effects

Solid Q1’20 driven by 35% growth in strategic brands FY’20 guidance reiterated despite COVID-19 effects Performance, not pipeline, to drive the share ST; BUY

Karl-Johan Bonnevier ...
  • Martin Arnell
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Viktor Trollsten

Northern Lights

Alexander Aukner ...
  • Joachim Gunell
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen
  • Stefan Gauffin

Northern Lights

Frank Maaø ...
  • Håkon Astrup
  • Jesper Ingildsen
  • Martin Arnell
  • Nicolas McBeath
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Rune Majlund Dahl
  • Simen Mortensen

Northern Lights

Alexander Aukner ...
  • Håkon Astrup
  • Helene Kvilhaug Brøndbo
  • Jon Masdal
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Martin Huseby Karlsen
  • Niklas Wetterling
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Simen Mortensen
  • Viktor Trollsten

Northern Lights

Frank Maaø ...
  • Martin Arnell
  • Mattias Holmberg
  • Nicolay Dyvik
  • Niklas Wetterling
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
  • Viktor Trollsten

Northern Lights

For H LUNDBECK A/S, the environment deterioration entails a downgrade to Neutral

H LUNDBECK A/S (DK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 3 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date May 15, 2020, the closing price was DKK 244.80 and its expected value was estimated at DKK 232.88.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

H. Lundbeck - AGM 24 March 2020

In general, H. Lundbeck ("Lundbeck") is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEMS 4.1 - 4.6 the (re-)election of the board of directors is proposed. In view of concerns over aggregate time commitments as well as other concerns, ECGS normally would have recommended opposition to the re-election of: Messrs. Lars Søren Rasmussen (ITEM 4.1), Lars Erik Holmqvist (ITEM 4.3), Jeremy Max Levin (ITEM 4.4) and Mr. Jeffrey Berkowitz (ITEM 4.5). However, considering that the proxy card does not permit this, it recommends ...

Expert Corporate Governance Service (ECGS)

H.Lundbeck, March 26 2019

In general, Lundbeck is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4.1, it is proposed to re-appoint Mr. Lars Soren Rasmussen as Chairman of  the board of directors. Although he is considered independent, ECGS notes that Mr. Rasmussen is currently chairing the Company's remuneration committee, which is not in accordance with its guidelines. ECGS furthermore notes a lack of female representation (22%) on the board and based on its guidelines the re-election of the chairman of the chairmanship (performing the dutie...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch